Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1

Drug Metabolism and Disposition

Volumn 30, Issue 7, 2002, Pages 763-770

  Luo, Feng R ^a   Paranjpe, Pankaj V ^b   Guo, Ailan ^c   Rubin, Eric ^d   Sinko, Patrick ^e  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

^e HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ELACRIDAR; GLYCOPROTEIN P; IRINOTECAN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; VERAPAMIL; VERLUKAST; CAMPTOTHECIN; CARRIER PROTEIN; DRUG DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2;

ARTICLE; CELL STRAIN; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG TRANSPORT; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE ABSORPTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TEMPERATURE DEPENDENCE; ANIMAL; BIOSYNTHESIS; CELL LINE; DIFFUSION CHAMBER; DOG; DOSE RESPONSE; INTESTINE MUCOSA; METABOLISM; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ANIMAL; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CAMPTOTHECIN; CELL LINE; DIFFUSION CHAMBERS, CULTURE; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMAN; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; ANIMALS; HUMANS; MEMBRANE TRANSPORT PROTEINS;

EID: 0035987891     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.30.7.763     Document Type: Article

References (41)

1. In vitro activation of irinotecan to SN-38 by human liver and intestine
2. Caco-2 monolayers in experimental and theoretical predictions of drug transport
3. The multidrug resistance protein family
4. Genetic dissection of the function of mammalian P-glycoprotein
5. An enhanced active efflux of CPT-11 and SN-38 in cisplatin-resistant human KB carcinoma cells
6. Possible involvement of P-glycoprotein in biliary excretion of CPT-11 in rats
7. Biliary excretion mechanism of CPT-11 and its metabolites in humans: Involvement of primary active transporters
8. Active efflux of CPT-11 and its metabolites in human KB-derived cell lines
9. Sequencing and tissue distribution of the canine MRP2 gene compared with MRP1 and MDR1
10. Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy
11. The S-phase cytotoxicity of camptothecin
12. Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors
13. FDA approves irinotecan as first-line therapy for colorectal cancer
14. P-glycoprotein and multidrug resistance
15. Correlation of mdr1 and cMOAT gene expression and irinotecan (CPT-11) efflux permeability in rat intestine
16. Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea
17. The intestinal absorption of camptothecin, a highly lipophilic drug, across Caco-2 cells is mediated by active transporter(s)
18. Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A
19. Clinical evaluation of sequential topoisomerase targeting in the treatment of advanced malignancy
20. Pharmacokinetics of orally administered camptothecins
21. Modification of the hydroxy lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity
22. Transport of a large neutral amino acid (phenylalanine) in a human intestinal epithelial cell line: Caco-2
23. CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein
24. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11
25. Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide *VP 16-213) enhance in vivo cytostatic activity and toxicity
26. Inhibition of intestinal P-glycoprotein and effects on etoposide absorption
27. Role of Intestinal P-glycoprotein (mdr1) in interpatient variation on the oral bioavailability of cyclosporine
28. Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells
29. Comparison of the permeability characterization of a human colonic epithelium (Caco-2) cell line to colon of rabbit, monkey and dog intestine and human drug absorption
30. Transport of topoisomerase 1 inhibitors by the breast cancer resistance protein. Potential clinical implications
31. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately upregulate these proteins in human colon carcinoma cells
32. The current status of camptothecin analogues as antitumor agents
33. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
34. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38 and its glucuronide: Role of canalicular multispecific organic anion transporter and P-glycoprotein
35. Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial caco-2 cell monolayers
36. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts
37. A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase 1 inhibitor
38. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics
39. Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells
40. Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations
41. Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts